| Title |
Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates
|
|---|---|
| Published in |
Clinical Infectious Diseases, July 2015
|
| DOI | 10.1093/cid/civ631 |
| Pubmed ID | |
| Authors |
Alimuddin Zumla, Markus Maeurer, for the Host-Directed Therapies Network Consortium, Alimuddin Zumla, Jeremiah Chakaya, Michael Hoelscher, Francine Ntoumi, Roxana Rustomjee, Cristina Vilaplana, Dorothy Yeboah-Manu, Voahangy Rasolof, Paula Munderi, Nalini Singh, Eleni Aklillu, Nesri Padayatchi, Eusebio Macete, Nathan Kapata, Modest Mulenga, Gibson Kibiki, Sayoki Mfinanga, Thomas Nyirenda, Leonard Mboko, Albert Garcia-Basteiro, Niaina Rakotosamimanana, Matthew Bates, Peter Mwaba, Klaus Reither, Sebestian Gagneux, Sarah Edwards, Elirehema Mfinanga, Salim Abdulla, Pere-Joan Cardona, James BW Russell, Vanya Gant, Mahdad Noursadeghi, Paul Elkington, Maryline Bonnet, Clara Menendez, Tandakha N. Dieye, Bassirou Diarra, Almoustapha Maiga, Abraham Aseffa, Shreemanta Parida, Christian Wejse, Eskild Petersen, Pontiano Kaleebu, Matt Oliver, Gill Craig, Tumena Corrah, Leopold Tientcheu, Martin Antonio, Timothy D. McHugh, Aziz Sheik, Giuseppe Ippolito, Gita Ramjee, Stefan H.E. Kaufmann, Gavin Churchyard, Adrie JC Steyn, Martin P. Grobusch, Ian Sanne, Neil Martinson, Rajhmun Mandansein, Robert J. Wilkinson, Robert S. Wallis, Bongani Mayosi, Marco Schito, Markus Maeurer |
| Abstract |
Tuberculosis (TB) remains a global emergency causing an estimated 1.5 million deaths annually. For several decades the major focus of TB treatment has been on antibiotic development targeting Mycobacterium tuberculosis (M.tb). The lengthy TB treatment duration and poor treatment outcomes associated with multi-drug resistant TB (MDR-TB) are of major concern. The sparse new TB drug pipeline and widespread emergence of MDR-TB signal an urgent need for more innovative interventions to improve treatment outcomes. Building on the historical Pasteur-Bechamp debates on the role of the 'microbe' versus the 'host internal milieu' in disease causation, we make the case for parallel investments into host-directed therapies (HDTs). A range of potential HDTs are now available which require evaluation in randomized controlled clinical trials as adjunct therapies for shortening the duration of TB therapy and improving treatment outcomes for drug-susceptible TB and MDR-TB. Funder initiatives that may enable further research into HDTs are described. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Madagascar | 1 | 20% |
| Unknown | 4 | 80% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Unknown | 123 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 17 | 14% |
| Researcher | 16 | 13% |
| Student > Master | 14 | 11% |
| Student > Bachelor | 11 | 9% |
| Other | 9 | 7% |
| Other | 31 | 25% |
| Unknown | 26 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 24% |
| Biochemistry, Genetics and Molecular Biology | 16 | 13% |
| Immunology and Microbiology | 15 | 12% |
| Agricultural and Biological Sciences | 9 | 7% |
| Nursing and Health Professions | 4 | 3% |
| Other | 17 | 14% |
| Unknown | 33 | 27% |